Overview

* Collegium Q3 revenue grows 31% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company raises full-year 2025 revenue and adjusted EBITDA guidance

Outlook

* Company raises full-year 2025 net revenue guidance to $775-$785 mln

* Collegium increases full-year 2025 adjusted EBITDA guidance to $460-$470 mln

* Company expects 2025 Jornay PM revenue between $145 mln and $150 mln

Result Drivers

* JORNAY PM GROWTH - 20% increase in prescriptions driven by back-to-school season, per CEO Vikram Karnani

* PAIN PORTFOLIO EXPANSION - Pain portfolio net revenue grew 11% yr/yr with all core products increasing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $209.40 $189.12

Revenue mln mln (5

Analysts

)

Q3 Beat $2.25 $2.04 (5

Adjusted Analysts

EPS )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Collegium Pharmaceutical Inc ( COLL ) is $45.00, about 20.3% above its November 5 closing price of $35.85

* The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)